The Spanish Agency for Medicines and Health Products (AEMPS), under the Ministry of Health, has issued a series of tips to solve the problems arising after knowing an increase in the demand of some of the similar medicines of the LPG-1, authorized to improveThe glycemic control in adults with type 2 diabetes mellitus (DM2) and, therefore, given possible problems in their supply if their prescriptions do not adjust.
The health authorities have detected supply problems due to the increase in consumption the drug of lilly 'Trulicity' of 0.75 mg and 1.5 mgthe usual demand of the medicine ";Something similar occurs with 'ozempic' 0.25 mg, 0.5 mg and 1 mg of injectable solution in preloaded pen, of Novo Nordisk "an intermittent availability" that could be maintained during the 2023 to continue increasing the demand.
In addition, Astrazeneca Pharmaceutical Spain, local representative of the owner of authorization for marketing of the drug 'Bydureon' 2 mg dust and solvent for injectable suspension of prolonged release in preloaded pen has reported that it plans to stop marketing this medication at the end of the year.
The AEMPS has asked to give priority to use these treatments to patients who cannot opt for other types of solution;And, as far as possible, new treatments are not initiated until pharmacists confirm that they can supply demand.To yourself while the supply problem persists, and given the possibility of not being able to initiate or continue the treatment due to the absence of the medicine in the market, it is recommended to replace the treatment other medications available from the same therapeutic group.
Thus, he recommends 'Byetta' (exenatida; administered by subcutaneous injection before meals 2 times a day);'Lyxumia' (Lixisenatida; administered by subcutaneous injection before the food 1 time);'Rybelsus' (semaglutida; administered orally once a day with an empty stomach and taken with half a glass of water and wait at least 30 minutes before eating or drinking or drinking other oral medications);and 'Victoza' (Liraglutida; administered by subcutaneous injection 1 time, at any time of the day, regardless of meals).